Johnson & Johnson is appealing the decision, which could be the first of many legal battles.
Both companies are under pressure to improve their performance.
Prescription drug prices have been rising over the past few years.
Pfizer hopes to run with its “little blue pill” as long as it can. That includes the time-honored strategy of launching its own generic.
Drug shortages are nothing new in U.S. hospitals.
The question is, who pays?
The European Union has some 20 "biosimilar" generics on the market; the US has one.
Drug makers are raising concerns Brexit could delay regulatory approval, slow down funding for basic research